Changes in the clinical symptoms of fibrocystic mastopathy during monotherapy with transdermal micronized progesterone: results of the BREAST-2 multicenter open prospective cohort study
Objective. To investigate the efficiency and safety of monotherapy with the transdermal micronized progesterone Progestogel for diffuse fibrocystic mastopathy. Materials and methods. The observational study enrolled 722 patients aged 37.1±0.3 years with preserved menstrual function and diagnosed diffuse fibrocystic mastopathy. The observation period consisted of a continuous medication usage period about 3 months (3 cycles), or, if necessary, a second course of as many as 6 months (6 cycles). The main criterion for the efficiency of the therapy was to estimate the number of masses, as evidenced by ultrasonography. During the study, the investigators made breast ultrasound and radiographic examinations, Breast Imaging-Reporting and Data System (BI-RADS) assessment, recorded pain intensity with a visual analogue scale (VAS), and assessed a patient’s health status according to the Clinical Global Impression Scale (CGI). Results. The clinical breast assessment throughout the investigation, by using the main efficiency criterion showed a decrease in the average number of masses in one patient during the treatment: 5.09±0.15 (before treatment), 2.97±0.13 (after 3-month therapy), and 2.29±0.16 (after 6-month therapy), (p < 0.001). There was a significant reduction in the signs of the disease, as assessed by ultrasonography of mass sizes (p <0.001). The changes in the breast detected by its clinical examination and mammography showed statistically significantly better BI-RADS scores (p < 0.001). Pain syndrome intensity assessment using the VAS demonstrated a significant decrease: 47.5±0.8 (before treatment), 13.5±0.6 (following 3 months), and 7.7 ± 0.8 (following 6 months) (p <0.001). Conclusion. The investigation provided evidence for the sufficient efficacy and safety profile of Progestogel monotherapy for fibrocystic mastopathy.Protasova A.E.
Keywords
fibrocystic mastopathy
mastalgia
mastodynia
Progestogel
micronized progesterone
References
- Tiffany Riley. Benign breast disease. Physician Assist. Clin. 2018; 3(3): 363-71.
- Marchant D.J. Benign breast disease. Obstet. Gynecol. Clin. North Am. 2002; 29(1): 1-20. https://dx.doi.org/10.1016/s0889-8545(03)00048-2.
- Чистяков Н.Н. Доброкачественные заболевания молочных желез. Клинические лекции. 2008: 57-8. [Chistyakov N.N. Benign diseases of the mammary glands. Clinical lectures. 2008: 57-8. (in Russian)].
- Colditz G.A., Bohlke K., Berkey C.S. Breast cancer risk accumulation starts early: prevention must also. Breast Cancer Res. Treat. 2014; 145(3): 567-79. https://dx.doi.org/10.1007/s10549-014-2993-8.
- Dyrstad S.W., Yan Y., Fowler A.M., Colditz G.A. Breast cancer risk associated with benign breast disease: systematic review and meta-analysis. Breast Cancer Res. Treat. 2015; 149(3): 569-75. https://dx.doi.org/10.1007/s10549-014-3254-6.
- Foulkes R., Gateley C.A. Management of benign diseases of the breast. Surgery (Oxford). 2010; 28(3): 125-9. https://dx.doi.org/10.1016/j.mpsur.2009.11.007.
- Меских Е.В., Рожкова Н.И. Применение прожестожеля при диффузных формах мастопатии. Опухоли женской репродуктивной системы. 2012; 1: 58-60. [Meskikh E.V., Rozhkova N.I. Application of progestogel in diffuse forms of mastopathy. Tumors of the female reproductive system, pharmacotherapy. 2012; 1: 58-60. (in Russian)].
- Радзинский В.Е., ред. Медицина молочной железы и гинекологические болезни. 2-е изд. М.: Редакция журнала StatusPraesens; 2017. 352 c. [Radzinsky V.E., ed. Medicine of breast and gynecological diseases. 2nd ed., revised and supplemented. Moscow: Editorial Board of the journal StatusPraesens; 2017. 352 p. (in Russian)].
- Orr B., Kelley J.L. Benign breast diseases: evaluation and management. Clin. Obstet. Gynecol. 2016; 59(4): 710-26. https://dx.doi.org/10.1097/GRF.0000000000000233.
- Запирова С.Б., Берщанская А.М., Чазова Н.Л., Рожкова Н.И. Особенности клинико-рентгено-соно-патоморфологических проявлений различных форм мастопатий. Медицинская визуализация. 2009; 5: 45-52. [Zapirova S.B., Bershchanskaya A.M., Chazova N.L., Rozhkova N.I. Features of clinical-x-ray-sono-pathomorphological manifestations of various forms of mastopathy. Medical visualization. 2009; 5: 45-52. (in Russian)].
- Rinaldi P., Ierardi C., Costantini M., Magno S., Giuliani M., Belli P., Bonomo L. Cystic breast lesions: sonographic findings and clinical management. J. Ultrasound Med. 2010; 29(11): 1617-26. https://dx.doi.org/10.7863/jum.2010.29.11.1617.
- Stachs A., Stubert J., Reimer T., Hartmann S. Benign breast disease in women. Dtsch. Arztebl. Int. 2019; 116(33-34): 565-74.
- Родионов В.В., Сметник А.А. Доброкачественные заболевания молочных желез. Акушерство и гинекология: новости, мнения, обучение. 2018; 1: 90-100. [Rodionov V.V., Smetnik A.A. Benign diseases of mammary glands. Obstetrics and gynecology: news, opinions, training. 2018; 1: 90-100. (in Russian)].
- Finlay-Schultz J., Sartorius C.A. Steroid hormones, steroid receptors, and breast cancer stem cells. J. Mammary Gland Biol. Neoplasia. 2015; 20(1-2): 39-50. https://dx.doi.org/10.1007/s10911-015-9340-5.
- Громовенко Е.Ю. Дисгормональные состояния молочных желез у женщин с сопутствующими нарушениями менструально-репродуктивной функции. Комплексный подход к обследованию и лечению молочных желез с применением аппликаций прогестерона как профилактика рака молочной железы. Таврический медико-биологический вестник. 2016; 19(2): 53-8. [Gromovenko E. Yu. Dishormonal conditions of mammary glands in women with concomitant disorders of menstrual and reproductive function. A comprehensive approach to the diagnosis and treatment of mammary glands with the use of the applications of progesterone as a prevention of breast cancer. Tavrichesky medico-biological Bulletin. 2016; 19 (2); 53-8. (in Russian)].
- Протасова А.Э., Андреева Е.Н., Рожкова Н.И., Вандеева Е.Н. Динамика клинических симптомов фиброзно-кистозной мастопатии на фоне трансдермального геля микронизированного прогестерона: результаты российского многоцентрового наблюдательного исследования БРЕСТ. Акушерство и гинекология. 2018; 11: 138-44. [Protasova A.E., Andreeva E.N., Rozhkova N.I., Vandeeva E.N. Dynamics of clinical symptoms of fibrocystic mastopathy against the background of transdermal gel of micronized progesterone: results of the Russian multicenter observational study BREST. Obstetrics and gynecology. 2018; 11: 138-44. (in Russian)]. https://dx.doi.org/10.18565/aig.2018.11.138-144.
- Прилепская В.Н., Бебнева Т.Н. Мастодиния: возможности терапии с применением микронизированного прогестерона. Клиническая практика. 2010; 3: 84-91. [Prilepskaya V.N., Bebneva T.N. Mastodinia: possibilities of therapy with the use of micronized progesterone. Clinical practice. 2010; 3: 84-91. (in Russian)].
- Андреева Е.Н., Рожкова Н.И. Эффективность трансдермального геля, содержащего микронизированный прогестерон, в лечении фиброзно-кистозной мастопатии (ФКМ). Результаты российского исследования. Акушерство и гинекология. 2016; 12: 131-6. [Andreeva E.N., Rozhkova N.I. Effectiveness of a transdermal gel containing micronized progesterone in the treatment of fibrocystic mastopathy (FCM). Results of the Russian study. Obstetrics and gynecology. 2016; 12: 131-6. (in Russian)]. https://dx.doi.org/10.18565/aig.2016.12.131-6.
- Протасова А.Э., Юренева С.В., Вандеева Е.Н. Менопаузальная гормональная терапия и факторы риска развития рака молочной железы. Гинекология. 2017; 19(3): 23-9. [Protasova A.E., Yureneva S.V., Vandeeva E.N. Menopausal hormone therapy and risk factors for development of breast cancer. Gynecology. 2017; 19(3): 23-9. (in Russian)].
- Brkic M., Vujovic S., Ivanisevic M., Ivovic M., Gajic M., Marina L. et al. The influence of progeserone gel therapy in the treatment of fibrocystic breast disease. Open J. Obstet. Gynecol. 2016; 6: 334-41.
Received 31.07.2020
Accepted 18.08.2020
About the Authors
Anna E. Protasova, MD, Professor of the Department of oncology, Faculty of medicine, Saint Petersburg State University; Professor of the Department of obstetrics and gynecology, V. A. Almazov National Medical Research Center Ministry of Health of Russia; Professor of the Department of oncology, I.I. Mechnikov North-Western State Medical University Ministry of Health of Russia; Head of the Department of oncology, AVA-PETER LLC. Tel.: +7(921)919-84-24. E-mail: protasova1966@yandex.ru.7-9 Universitetskaya nab., Saint Petersburg, 199034, Russia; 2 Akkuratova str., Saint Petersburg, 197341, Russia; 41 Kirochnaya str., Saint Petersburg,
191015, Russia; 22-24 lit. A pom. 50-N, Nevsky Ave., Saint Petersburg, 191186, Russia.
For citation: Protasova A.E. Changes in the clinical symptoms of fibrocystic mastopathy during monotherapy with transdermal micronized progesterone: results of the BREAST-2 multicenter open prospective cohort study.
Akusherstvo i Ginekologiya/ Obstetrics and Gynecology. 2020; 8: 159-168 (in Russian).
https://dx.doi.org/10.18565/aig.2020.8.159-168
Similar Articles
